Site Editors

Shaji K. Kumar, MD

Prashant Kapoor, MD, FACP

Advertisement
Advertisement

FDA Approves Talquetamab-tgvs for Treatment of Relapsed or Refractory Multiple Myeloma

By: JNCCN 360 Staff
Posted: Friday, August 11, 2023

On August 9, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval of talquetamab-tgvs (Talvey), a first-in-class bispecific antibody for the treatment of adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy (including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody). Continued approval for this indication is contingent upon verification and description of clinical benefit in confirmatory trial(s).

This accelerated approval is based on the phase II MonumenTAL-1 study, which included 32 patients who had received at least four prior lines of therapy and who were not exposed to prior T-cell redirection therapy (n = 187). At the subcutaneous biweekly dose of 0.8 mg/kg, the overall response rate was 73.6% (95% confidence interval [CI] = 63.0%–82.4%). With a median follow-up of nearly 6 months from first response among responders, 58% of patients achieved a very good partial response or better, including a complete response rate of 33%. At the subcutaneous weekly dose of 0.4 mg/kg, the overall response rate was 73.0% (95% CI = 63.2%–81.4%). With a median follow-up of nearly 14 months from first response among responders, 57% of patients achieved a very good partial response or better, including a complete response rate of 35%.

The median duration of response was not reached with the 0.8 mg/kg subcutaneous biweekly dose group and 9.5 months with the 0.4 mg/kg subcutaneous weekly dose. Among patients receiving the 0.8 mg/kg subcutaneous biweekly dose, an estimated 85% of responders maintained response for at least 9 months.

The safety profile for talquetamab includes a boxed warning for cytokine-release syndrome and neurologic toxicity including immune effector cell–associated neurotoxicity syndrome; warnings and precautions include oral toxicity and weight loss, infections, cytopenias, skin toxicity, hepatoxicity, and embryofetal toxicity. Talquetamab is available only through a restricted program called the Tecvayli and Talvey Risk Evaluation and Mitigation Strategy.


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.